Olema Pharmaceuticals (OLMA) Cash & Equivalents (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Cash & Equivalents for 7 consecutive years, with $52.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 3.77% year-over-year to $52.5 million; the TTM figure through Mar 2026 stood at $52.5 million (up 3.77% YoY), while the FY2025 annual figure was $48.3 million, down 65.37% from the prior year.
• Cash & Equivalents climbed to $52.5 million in Q1 2026 per OLMA's latest filing, from $48.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $139.5 million in Q4 2024 and bottomed at $16.9 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $48.4 million across 5 years, with a median of $35.9 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents soared 338.02% — and 2024, when it tumbled 69.43%.
• Olema Pharmaceuticals' Cash & Equivalents stood at $23.7 million in 2022, then jumped by 189.17% to $68.5 million in 2023, then jumped by 103.5% to $139.5 million in 2024, then tumbled by 65.37% to $48.3 million in 2025, then grew by 8.79% to $52.5 million in 2026.
• Business Quant data shows OLMA's Cash & Equivalents at $52.5 million in Q1 2026, $48.3 million in Q4 2025, and $35.3 million in Q3 2025.